This study is investigating two medications, ubamatamab and REGN7075, to see if they can help treat advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC). Another medication, sarilumab, is also being studied to see if it can help manage immune-related side effects from ubamatamab. Researchers will look at how well ubamatamab and REGN7075 work, what side effects they might cause, and how much of the drugs are in your blood. They will also check if your body makes antibodies against these drugs, which could affect how well they work. You may be eligible if you are an adult with advanced or metastatic NSCLC who has already received standard first-line treatment. The study aims to measure how many participants respond to the treatment over a period of up to 5 years. The current status of this study is unclear, and it plans to enroll 300 participants.

Study design

This is an interventional study with a planned enrollment of 300 adult participants. The phase of the study is not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for objective response to treatment for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.